This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Insulin-like growth factor-1 receptor (IGF1R; CD221)	*In vitro* and mouse studies suggest that a class of IGF1R inhibitors could help treat cancer. *In vitro*, a lead phenylquinoline compound inhibited growth of multiple human cancer cell lines at low nanomolar concentrations. In liver cells, the compound inhibited activation of oncogenic IGF1R compared with vehicle. In mice with xenograft liver tumors, an analog of the lead compound decreased tumor growth more than doxorubicin, a generic chemotherapeutic. Ongoing studies include testing the analog in animal models of brain and breast cancers. OSI-906, an IGF1R inhibitor from Astellas Pharma Inc., is in Phase III testing to treat adrenocortical carcinoma. At least four other companies have IGF1R inhibitors in Phase II testing to treat various cancers. ***SciBX*** **3(48); doi:10.1038/scibx.2010.1440** **Published online Dec. 16, 2010**	Patented by Efficient Pharma Management Corp.; available for licensing or partnering	Chou, L.-C. *et al. J. Med. Chem.*; published online Oct. 25, 2010; doi:10.1021/jm100780c **Contact:** Sheng-Chu Kuo, China Medical University, Taichung, Taiwan e-mail: sckuo@mail.cmu.edu.tw **Contact:** Li-Jiau Huang, same affiliation as above e-mail: ljhuang@mail.cmu.edu.tw